

Review

Open Access

## Recent advances in the bcr-abl negative chronic myeloproliferative diseases

Michael Bennett\*<sup>1</sup> and David F Stroncek<sup>2</sup>

Address: <sup>1</sup>Department of Hematology, Ha'Emek Medical Center, Afula, Israel and <sup>2</sup>Department of Transfusional Medicine, National Institutes of Health, Bethesda, Maryland, USA

Email: Michael Bennett\* - benet\_m@clalit.org.il; David F Stroncek - dstroncek@mail.cc.nih.gov

\* Corresponding author

Published: 11 October 2006

Received: 15 August 2006

*Journal of Translational Medicine* 2006, **4**:41 doi:10.1186/1479-5876-4-41

Accepted: 11 October 2006

This article is available from: <http://www.translational-medicine.com/content/4/1/41>

© 2006 Bennett and Stroncek; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

The chronic myeloproliferative disorders are clonal hematopoietic stem cell disorders of unknown etiology. In one of these (chronic myeloid leukemia), there is an associated pathognomonic chromosomal abnormality known as the Philadelphia chromosome. This leads to constitutive tyrosine kinase activity which is responsible for the disease and is used as a target for effective therapy. This review concentrates on the search in the other conditions (polycythemia vera, essential thrombocythemia and idiopathic myelofibrosis) for a similar biological marker with therapeutic potential. There is no obvious chromosomal marker in these conditions and yet evidence of clonality can be obtained in females by the use of X-inactivation patterns. *PRV-1* mRNA over expression, raised vitamin B<sub>12</sub> levels and raised neutrophil alkaline phosphatase scores are evidence that cells in these conditions have received excessive signals for proliferation, maturation and reduced apoptosis. The ability of erythroid colonies to grow spontaneously without added external erythropoietin in some cases, provided a useful marker and a clue to this abnormal signaling. In the past year several important discoveries have been made which go a long way in elucidating the involved pathways. The recently discovered *JAK2* V617F mutation which occurs in the majority of cases of polycythemia vera and in about half of the cases with the two other conditions, enables constitutive tyrosine kinase activity without the need for ligand binding to hematopoietic receptors. This mutation has become the biological marker for these conditions and has spurred the development of a specific therapy to neutralize its effects. The realization that inherited mutations in the thrombopoietin receptor (c-Mpl) can cause a phenotype of thrombocytosis such as in Mpl Baltimore (K39N) and in a Japanese family with S505A, has prompted the search for acquired mutations in this receptor in chronic myeloproliferative disease. Recently, two mutations have been found; W515L and W515K. These mutations have been evident in patients with essential thrombocythemia and idiopathic myelofibrosis but not in polycythemia vera. They presumably act by causing constitutional, activating conformational changes in the receptor. The discovery of *JAK2* and Mpl mutations is leading to rapid advancements in understanding the pathophysiology and in the treatment of these diseases.

## Introduction

The concept of the myeloproliferative disorders was introduced by Dameshek more than 50 years ago [1]. He suggested then that these conditions were "closely interrelated" and due to a proliferative activity of the bone marrow by an undiscovered stimulus. In the case of one these conditions, chronic myeloid leukemia (CML), the stimulus became evident with the discovery of the Philadelphia chromosome and the translocation which results in the BCR/ABL fusion gene. This abnormal gene codes for a protein which has constitutive tyrosine kinase activity in cellular signaling pathways controlling proliferation and differentiation. The marrow is therefore chronically stimulated not due to excess external signals as suggested by Dameshek, but due to a fault in the signaling pathway itself caused by the translocation. As a result of these discoveries CML is now considered a separate entity and has a specific and effective therapy.

The other three main chronic myeloproliferative diseases are today recognized as Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis (IMF). These conditions are clonal disorders of hematopoietic progenitor cells which have the capacity to differentiate into excess numbers of mature cells. In PV the emphasis is on an excess production of red cells leading to a raised hematocrit and possible thrombotic complications if left untreated. Raised neutrophil and platelet counts may also be evident. In ET the emphasis is very much on an excessive production of platelets which may be markedly raised and result in a bleeding or a thrombotic tendency. The neutrophil count may also be raised but the hematocrit is normal. These two conditions are associated with a long median survival if patients do not suffer thrombotic or hemostatic complications. The third disease in this category, IMF, has however, a worse prognosis with a median survival that may be only 3.5 to 5 years [2]. In this condition there is fibrosis within the bone marrow leading to extramedullary hematopoiesis, enlargement of the spleen and bone marrow failure. Fibrosis is a secondary phenomenon due to release of cytokines from neoplastic megakaryocytes. This condition may occur in a patient with previous PV or ET, or may occur without any evident antecedent disease.

### **The search for biological markers in chronic myeloproliferative disease**

Molecular markers for chronic myeloproliferative diseases, such as the Philadelphia chromosome in CML, have long been searched for, but little progress has been made until recently. While visible chromosomal abnormalities can be detected in about 33% of patients with PV [3] no single abnormality is pathognomonic for PV, ET, or IMF as the Philadelphia chromosome is for CML. Recurrent chromosomal abnormalities have however been docu-

mented. A 20q deletion occurs in 10% of patients with PV and IMF, but the most common abnormality is the finding of a loss of heterozygosity of 9p in up to 33% of PV patients [4]. In ET detection of karyotype abnormalities is infrequent [3].

The lack of a chromosomal marker in PV and ET in particular leads to diagnostic difficulties. The diagnosis of both of these disorders has largely been by exclusion of conditions known to cause an elevated hematocrit or platelet count. A search has therefore been underway for many years for positive pathological features which could help in establishing the diagnosis. For many years clinical criteria was supplemented with the result of testing for clonal or abnormal hematopoiesis. More recently, molecular markers have been identified that are proving to be useful in the diagnosis of these diseases.

### *Clonal hematopoiesis*

The first useful marker for chronic myeloproliferative disease was the detection of clonal hematopoiesis. Initially the use of X-inactivation patterns in females established clonality in cell lineages such as granulocytes [5-7]. However, these assays were technically demanding and not widely available.

### *Endogenous erythroid colonies*

The measurement of endogenous colonies has been an important marker for diagnosing PV. In normal individuals erythroid colonies will only grow in culture media supplemented with erythropoietin (EPO). A characteristic feature of PV is the ability for erythroid progenitor cells obtained from blood or bone marrow to grow in semi-solid, serum-containing cultures in the absence of EPO [8]. This "spontaneous" growth of erythroid colonies is known as endogenous erythroid colony (EEC) formation and is also observed in some cases of ET and IMF, but not in normal subjects. The formation of EEC was thought at first to be due to hypersensitivity of these cells to minute quantities of EPO in the culture media [9] as well as other growth factors such as IL-3, stem cell factor, GM-CSF, thrombopoietin (TPO) and insulin like growth factor (IGF-1) [10-13]. This augmented response of erythroid progenitors to growth factors suggested that these cells had an abnormality in the EPO signaling mechanism that controlled the processes of erythroid proliferation, maturation and apoptosis. The situation is similar in CML where the BCR/ABL protein conveys constitutive tyrosine kinase activity. Later, it became clear, however, that growth of these colonies was truly independent of EPO since it was not blocked by anti-EPO neutralizing antibodies [14].

Although the detection of EEC is a laborious procedure, requires adequate standardization and is not freely avail-

able to many centers, it is accepted as a major diagnostic criteria for PV according to WHO and European recommendations [15].

EPO levels are typically low in PV, but this finding is only accepted as a minor criteria according to these recommendations.

Spontaneous megakaryocytic colonies can also be grown without thrombopoietin in chronic myeloproliferative disease. Although first described as a useful test to discriminate between ET and reactive thrombocytosis or normal subjects [16], spontaneous colonies can also be seen in PV and IMF [17,18].

#### *PRV-1 mRNA over-expression and CD177*

The first useful molecular marker of chronic myeloproliferative diseases was the measurement of granulocyte levels of *PRV-1* mRNA. [19] Several studies have suggested that the granulocyte over-production of *PRV-1* mRNA was a marker of clonal hematopoiesis in PV [20-22]. These studies have found that approximately 69 to 91% of PV patients have elevated granulocyte *PRV-1* mRNA levels. Others have found increased expression in every patient with PV [23]. This variability may be due differences in sample handling. The time that elapses prior to processing of blood samples after collection may be a crucial factor [24]. The use of whole blood rather than purified granulocytes and the choice of the housekeeping gene used to compare gene expression may also be important [25]. Granulocyte *PRV-1* mRNA levels have also been found to be elevated in approximately 17 to 67% of patients with ET [20-22] and 46% with IMF [20].

Unfortunately elevations in granulocyte *PRV-1* mRNA levels are not as specific for the chronic myeloproliferative diseases as initially believed. Levels of granulocyte *PRV-1* mRNA can be transiently elevated in healthy subjects. *PRV-1* is a member of the uPAR/Ly6/CD59 family of receptors. The gene *PRV-1*, and the gene encoding a neutrophil alloantigen, *NB1*, are alleles of a single gene, *CD177*, in chromosome band 19q13.31 [26]. *CD177* glycoprotein can be recognized in neutrophil plasma membranes by immunofluorescence on analysis with monoclonal antibodies. In normal individuals only about 50% of neutrophils express *CD177*. The numbers are higher in women and increase in pregnancy, with infection and after G-CSF administration [27]. Granulocyte *PRV-1* mRNA levels are also increased in healthy subjects given G-CSF or with infection. Neutrophil *CD177* antigen density per cell is also increased in patients with PV [28], however, flow cytometry measurement of neutrophil *CD177* expression cannot be used in the diagnosis of PV since the numbers of *CD177* positive neutrophils is not consistently elevated compared to controls [29]. The

explanation for the lack of association in PV patients between *CD177* expression at the mRNA level and cell surface *CD177* protein expression is not apparent. It may be due to a fault in processing or due to a release of the protein into plasma. This is the case in other similar proteins which have a GPI (glycosyl-phosphatidylinositol) attachment [30].

It appears that the increased *PRV-1* mRNA levels are a secondary phenomenon to myeloproliferation rather than the cause of the abnormal hematopoiesis. Other useful biomarkers such as high plasma vitamin B12 levels and raised neutrophil alkaline phosphatase scores are also secondary events

#### **JAK2 V617F**

A specific mutation in the Janus kinase, JAK2, has been identified in the majority of patients with PV and in many patients with ET and IMF. The presence of this somatic mutation in myeloid cells has proven to be more specific for myeloproliferative diseases than elevated *PRV-1* mRNA levels and its assessment has now become a standard molecular assay for the diagnosis of PV.


#### *The Janus Kinases*

The receptors for EPO, G-CSF, GM-CSF, TPO and some interleukins are termed type I cytokine receptors. These are characterized by a lack of a cytoplasmic tyrosine kinase domain and instead use an intracellular JAK-STAT pathway to initiate signaling [31]. The STAT pathway refers to Signal Transducers and Activators of Transcription which are responsible for directly influencing gene expression. JAK refers to the Janus Kinases, named after the Greek-Roman god of gates and passageways. Initially one kinase involved in this system was identified and this was skeptically nicknamed "just another kinase". Three more members of this family have been found and they are now recognized to be crucially important in growth factor and cytokine signaling. JAK-2 was the third Janus kinase discovered and it is involved in haemopoietic receptor signaling for EPO, G-CSF, GM-CSF and TPO.

JAKs bind to juxtamembrane cytoplasmic regions of type I cytokine receptors by their FERM (Four-point-one, Ezrin, Radixin, Moesin) domain. In the unliganded state, the receptor exists as a dimer separated by 73 Å. After binding with an activating ligand, a conformational change occurs resulting in the reduction of the separation of the two strands to 39 Å [32]. This allows close apposition of two bound JAK-2 molecules and their mutual activation by cross-phosphorylation. Once activated JAK-2 exerts kinase action via its JH1 domain initially on the receptor itself providing docking sites for STATs and later for other signaling and regulatory elements.

In addition to the FERM domain, JAK2 has two other domains JH1 and JH2. The JH1 domain is situated near the carboxyl terminal of the protein. Proximal to this is a JH2 domain which has no kinase activity, but normally prevents the kinase activity of JH1 by interacting with its

activation loop. When ligand binds, the resulting conformational changes in the receptor and in the bound JAK-2 cause a separation of the JH2 inhibitory domain from JH1. This leads to the expression of kinase activity (Figure 1) [33,34].



**Figure 1**  
**The domains of JAK2 illustrating binding to the receptor and changes consequent to receptor binding and mutation in the JH2 domain.** The V617F mutation of the JH2 domain of JAK2 results in constitutive kinase activation. Panel A: When no ligand is bound to the EPO, TPO, G-CSF or GM-CSF receptors, the kinase activity of the JH1 domain is inhibited by the JH2 domain and JAK2 is inactive. Panel B: When EPO binding to its receptor, JAK2 changes conformation, the JH1 kinase activity is no longer inhibited by JH2. Panel C: The JAK2 V617F mutation prevents JH2 from inhibiting JH1 and the kinase is active even when no ligand is bound by the receptor.

### *The importance of the JAK2 V617F mutation*

The critical role of JAK2 in signal transduction by hematopoietic growth factor and cytokine receptors suggested that JAK2 might have abnormal tyrosine kinase activity in chronic myeloproliferative disease. In *Drosophila* a mutation in the JH2 domain causes a leukemia like picture due to hyper activation of the JAK-STAT pathways [35]. In the spring of 2005, almost simultaneously, five reports appeared describing a mutation in the gene coding for JAK2 also in this pseudo kinase JH2 domain, in patients with chronic myeloproliferative diseases [36-40]. This was a G to T mutation at nucleotide 1849, which leads to phenylalanine being substituted for valine at codon 617 (V617F). This mutation leads to a lack of inhibition of the JH1 domain and constitutive JAK2 kinase activity without the coupling of ligands to hemopoietic receptors.

The mutation occurs mainly in PV with a frequency of between 76% and 97% depending upon the method of detection used and the accuracy in the diagnosis of PV. It is less common in patients with ET (29–57%) and IMF (50%). Most patients have a heterozygous mutation, but in 30% the mutation is homozygous due to mitotic recombination corresponding to LOH and more advanced disease [4,38,39,41]. Analysis of BFU-e cells after cell culture however, has shown homozygous mutations in all cases of PV, but not in ET unless they developed a PV phenotype [42]. This mutation is found only occasionally in other hematological diseases: 3% in patients with chronic myelomonocytic leukemia, 5% in other myelodysplastic syndromes, 2 out of 8 patients with systemic mastocytosis, 1 out of 6 with chronic neutrophilic leukemia and none out of 11 patients with the hypereosinophilic syndrome [69]. It has also been found in 6 out of 9 patients with refractory anemia with ringed sideroblasts and thrombocytosis [43].

JAK2 V617F very likely has an important role in the pathobiology of PV, since it gives cells with the mutation a proliferative advantage. In vitro studies have found that cells transfected with JAK2 V617F had a proliferation and survival advantage over wild type JAK2 transfected cells. The JAK2 V617F transfected cells were more sensitive to stimulatory signals [44]. Cells transfected with JAK2 V617F were also able to activate STAT mediated transcription in the absence of erythropoietin, but cells transfected with wild-type JAK2 did not [37]. Mice transplanted with bone marrow cells infected with murine JAK2 V617F developed erythrocytosis four weeks after transplant but not mice transplanted with cells transfected with murine wild-type JAK2 [37].

In ET, patients with JAK2 V617F have a significantly higher Hb level than without the mutation [45-47], suggesting that these patients are more similar to PV. The

detection of this mutation by PCR in ET which can detect 2–4% of mutated cells, is more sensitive as a test for clonality than X-chromosome inactivation patterns which require at least 26% mutated cells. There are, however, cases of ET who have monoclonal hematopoiesis according to X-chromosome inactivation patterns but are negative for the JAK2 mutation [48], suggesting that in these another mutation may be present. This may also be the case in those patients with true PV who have EEC and monoclonal hematopoiesis but who do not have the JAK2 mutation.

Many of the markers previously useful in the diagnosis of PV and ET may be due to a downstream effect of JAK2 activation. The myeloproliferation that results from constitutive JAK2 activation could result in increased neutrophil alkaline phosphatase scores, increased levels of vitamin B<sub>12</sub> (due to increased transcobalamin I) and CD177 mRNA overexpression. Interestingly, CD177 mRNA is also overexpressed by neutrophils from healthy subjects given G-CSF [28]. Since G-CSF stimulates neutrophils by binding to the G-CSF receptor and activating JAK2, this provides further evidence that JAK2 overactivation is likely responsible for the overexpression of CD177 mRNA in patients with PV.

The fact that JAK2 constitutive activation due to the V617F mutation occurs in PV, ET and IMF suggests that those with this mutation are part of a common disease with different expression due to other factors such as disease duration. It is also possible that the different phenotypes are due to additional mutations influencing for instance megakaryocytes and platelet production. This has now become apparent with the discovery of c-Mpl mutations in some cases (see later).

Using very sensitive techniques the JAK2 V617F has been detected in up to 10% of healthy donors with normal blood counts [49]. This suggests that the mutation may occur as an early event in the development of the disease or other factors are required for disease development. This is seen in CML where BCR/ABL expression can occur in normal individuals using sensitive techniques [50,51]. BCR/ABL specific T cells have also been found in healthy individuals [52] which suggests an immune mechanism for control of the disease.

### **Mutations in Cytokine receptors**

The possibility that an acquired mutation in a cytokine receptor may be responsible for myeloproliferative disease has been suspected but until now none have been found. Inherited mutations with a proliferative phenotype are however occasionally seen. With the erythropoietin receptor (EpoR) for example, a truncated receptor with loss of the cytoplasmic carboxyl terminal leads to familial

polycythemia [14]. In this mutation there is loss of the docking site for SHP1 which normally would dephosphorylate JAK2. Prolonged phosphorylation of JAK2/STAT5 and prolonged erythropoietin "on" signals lead to a high hematocrit.

Mutations have been found in the G-CSF (G-CSFR) receptor in some patients with severe congenital neutropenia [53]. These initially have germline ELA-2 mutations which cause neutrophil elastase deficiency and then develop a secondary somatic mutation in the G-CSFR. This occurs in the terminal cytoplasmic region responsible for the binding of SHP-1 and SOCS (suppression of cytokine signaling) proteins leading to a hyperproliferative response [54]. Many of these patients go on to develop acute myeloid leukemia.

### The thrombopoietin receptor (c-Mpl)

Abnormalities of the thrombopoietin receptor known as c-Mpl have been suspected of being involved in myeloproliferative diseases. In fact, c-Mpl was initially identified as a proto-oncogene when its transmembranous and intracellular domains were transduced into the envelope of the myeloproliferative leukemia virus (MPLV) [55]. In mice this virus causes a generalized myeloproliferative polycythemic-like disorder with granulocytosis, thrombocytosis and erythroblastosis [56]. This proliferation might be due to loss of the extracellular domain which is thought to exert an inhibitory effect. Truncation of this area of c-Mpl causes TPO independent growth [57]. TPO might exert its influence by leading to a relief of this block.

The expression of c-Mpl has been found to be reduced in ET [58], PV and IMF [59]. This is related to incomplete c-Mpl glycosylation rather than c-Mpl gene disruption or transcriptional repression [60]. The expression of c-Mpl is, however, also reduced in reactive thrombocytosis [61] and in hereditary thrombocytosis caused by a TPO gene mutation [62], showing that these findings are not specific for myeloproliferative disease.

### Inherited mutations in c-Mpl


The recent discovery of two inherited mutations in *c-Mpl* has fueled the search for acquired mutations in these disorders. The first inherited mutation discovered was in a Japanese family known to have "Familial" Essential Thrombocythemia inherited in an autosomal dominant manner. Here there is an amino acid change from serine to asparagine in position 505 in the receptor (S505A), resulting from a heterozygous G to A nucleotide substitution at position 1073 in exon 10 of *c-MPL* [63]. This mutation occurs in the transmembranous portion of the receptor and leads to constitutive activity of the receptor. The second c-Mpl mutation found was Mpl Baltimore, K39N [64], which is a polymorphism near the terminal

portion of the extra-cellular portion of the receptor (Figure 2). This results from a single base change guanosine to thymidine at nucleotide 1238 in exon 2 and is found exclusively in African Americans with a gene frequency of 7%. Heterozygotes have elevated platelet counts as compared to controls and homozygotes have even higher counts, in excess of  $800 \times 10^9/L$ .

The reason why these *c-Mpl* polymorphisms should cause thrombocytosis is not entirely clear. They could allow the receptor to assume an active configuration involving the closer proximity of the two strands of the receptor dimer and consequent JAK2 activation.

### Acquired 515 mutations in c-Mpl

Recently it was suggested that abnormalities within a 5-amino acid amphipathic motif (RWQFP in humans) which is a juxtamembranal domain of the c-Mpl receptor, leads to constitutive activation [65]. This area, which extends from 514 to 518, is thought to prevent the two strands of the c-Mpl dimer from approximating when ligand is not bound to the receptor (Figure 2). Two acquired mutations have now been found at position 515 within this motif, W515L [66] and W515K [67]. These reports present the first evidence of a somatic mutation in a cytokine receptor in chronic myeloproliferative diseases.



**Figure 2**  
**Polymorphism and mutations of the thrombopoietin receptor, c-Mpl.** Two polymorphisms, c-Mpl K39N and S505A, lead to constitutive activity of c-Mpl and thrombocytosis. Somatic mutations in the juxtamembranal domain of c-Mpl also lead to constitutive activity and have been found in patients with ET and IMF.



In 1182 patients '515' mutations were found in 20 [67]. Amongst the ET patients mutations were found in 1% and amongst the IMF patients they were found in 4–5%. The mutation was seen in 6 patients who were also *JAK2* V617F heterozygous. It was not clear whether the *JAK2* and *c-Mpl* mutations were in two separate clones or represent two mutations in the same clone. Two cases had a mixed clonal state with both '515' mutations. The 515 mutations were not seen in PV suggesting in this disease *JAK2* V617F is prominent and is related to the phenotype of red cell production. In contrast, *c-Mpl* mutations affect megakaryocytes and lead to IMF and ET. The *MPL515* mutations that have been detected thus far described are infrequent, but it is expected that further *c-Mpl* mutations will be discovered.

### Conclusion

The identification of specific molecular mutations in patients with chronic myeloproliferative disease has been a significant clinical advancement. There is no doubt, that the discovery of the *JAK2* V617F mutation represents a major advance in understanding the pathophysiology of these disorders. It is an aid to diagnosis in some cases and will no doubt lead to the development of specific therapy in the future.

The identification of granulocyte *JAK2* V617F is highly specific for the diagnosis of PV and has rapidly replaced other biochemical, cellular, and molecular diagnostic assays. The presence of *JAK2* V617F is also useful in evaluating patients with elevated platelet counts who are suspected of having ET, although only approximately half of all ET patients have *JAK2*V617F. Many clinical investigators are evaluating *c-Mpl* for mutations and polymorphisms in these ET patients with and without *JAK2* mutations. Some ET patients will have *c-Mpl* mutations, but the exact role of *c-Mpl* mutations in ET is not yet certain. ET is certainly a heterogeneous disease. It needs to be separated from IMF and prodromal IMF by careful histological analysis of bone marrow biopsy specimens [68] and from latent PV. The importance of the polyclonal versus the monoclonal forms of the disease need to be ascertained. It is hoped that molecular markers will help in this regard.

The identification of an activating mutation in *JAK2* as a cause of chronic myeloproliferative disease could have important clinical implications. The development of specific inhibitors of the BCR/ABL kinase found in patients with CML has had a remarkable clinical impact. They are highly effective and have little toxicity. Specific inhibitors of the abnormal *JAK2* kinase are not yet available, but will likely be tested and available in the near future. Since the therapeutic modalities available to treat chronic myeloproliferative diseases are limited to phlebotomy, platelet

inhibitors, cytotoxic drugs and in some cases allogeneic stem cell transplantation, the availability of an effective and specific molecular therapy would be an enormous advance.

While mutations in *JAK2* may not be the molecular defect that initiates PV, ET or IMF, the discovery of this molecular marker has made the diagnosis of PV and ET simpler, faster and more precise. The more precise diagnosis and classification of these patients will surely lead to more rapid advances of clinical investigations aimed at further defining the pathophysiology and more effective treatment of these diseases.

Dameshek showed outstanding foresight in recognizing and grouping together the chronic myeloproliferative diseases. This has led to developments in our understanding of their common pathophysiological mechanisms and the peculiar molecular events in each disease category resulting in different phenotypes. These are exciting times with new discoveries coming at a tremendous pace. All of this will no doubt eventually lead to the development of specific therapy and improved care for these patients.

### Competing interests

Both authors were involved in composing this manuscript and both declare that they have no competing interests in the publication of this article.

### References

1. Dameshek W: **Some speculations on the myeloproliferative syndromes.** *Blood* 1951, **6(4)**:372-375.
2. Cervantes F: **Modern management of myelofibrosis.** *Br J Haematol* 2005, **128(5)**:583-592.
3. Bench AJ, Cross NC, Huntly BJ, Nacheva EP, Green AR: **Myeloproliferative disorders.** *Best Pract Res Clin Haematol* 2001, **14(3)**:531-551.
4. Kralovics R, Guan Y, Prchal JT: **Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera.** *Exp Hematol* 2002, **30(3)**:229-236.
5. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L: **Polycythemia vera: stem-cell and probable clonal origin of the disease.** *N Engl J Med* 1976, **295(17)**:913-916.
6. Jacobson RJ, Salo A, Fialkow PJ: **Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis.** *Blood* 1978, **51(2)**:189-194.
7. Fialkow PJ, Faguette GB, Jacobson RJ, Vaidya K, Murphy S: **Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell.** *Blood* 1981, **58(5)**:916-919.
8. Prchal JF, Axelrad AA: **Letter: Bone-marrow responses in polycythemia vera.** *N Engl J Med* 1974, **290(24)**:1382.
9. Zanjani ED, Lutton JD, Hoffman R, Wasserman LR: **Erythroid colony formation by polycythemia vera bone marrow in vitro. Dependence on erythropoietin.** *J Clin Invest* 1977, **59(5)**:841-848.
10. Dai CH, Krantz SB, Dessypris EN, Means RT Jr., Horn ST, Gilbert HS: **Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor.** *Blood* 1992, **80(4)**:891-899.
11. Dai CH, Krantz SB, Koury ST, Kollar K: **Polycythemia vera. IV. Specific binding of stem cell factor to normal and polycythemia vera highly purified erythroid progenitor cells.** *Br J Haematol* 1994, **88(3)**:497-505.

12. Correa PN, Eskinazi D, Axelrad AA: **Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-I in vitro: studies in an improved serum-free medium.** *Blood* 1994, **83(1)**:99-112.
13. Axelrad AA, Eskinazi D, Correa PN, Amato D: **Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia.** *Blood* 2000, **96(10)**:3310-3321.
14. Maran J, Prchal J: **Polycythemia and oxygen sensing.** *Pathol Biol (Paris)* 2004, **52(5)**:280-284.
15. Michiels JJ, Raeve HD, Berneman Z, Bockstaele DV, Hebeda K, Lam K, Schroyens W: **The 2001 world health organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.** *Semin Thromb Hemost* 2006, **32(4)**:307-340.
16. Rolovic Z, Basara N, Gotic M, Sefer D, Bogdanovic A: **The determination of spontaneous megakaryocyte colony formation is an unequivocal test for discrimination between essential thrombocythemia and reactive thrombocytosis.** *Br J Haematol* 1995, **90(2)**:326-331.
17. Escoffre-Barbe M, Amiot L, Beaucournu P, Jegu P, Grulois I, Grosbois B, Bernard M, Fest T, Lamy T, Fardel O: **Spontaneous megakaryocytic colony formation does not discriminate between essential thrombocythemia and polycythemia vera.** *Am J Hematol* 2006, **81(7)**:554-556.
18. Taksin AL, Couedic JP, Dusanter-Fourt I, Masse A, Giraudier S, Katz A, Wendling F, Vainchenker W, Casadevall N, Debili N: **Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L.** *Blood* 1999, **93(1)**:125-139.
19. Temerinac S, Klippel S, Strunck E, Roder S, Lubbert M, Lange W, Azemar M, Meinhardt G, Schaefer HE, Pahl HL: **Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera.** *Blood* 2000, **95(8)**:2569-2576.
20. Kralovics R, Buser AS, Teo SS, Coers J, Tichelli A, van der Maas AP, Skoda RC: **Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders.** *Blood* 2003, **102(5)**:1869-1871.
21. Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT: **Discrimination of polycythemia and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin.** *Blood* 2003, **101(8)**:3294-3301.
22. Ricksten A, Palmqvist L, Wasslavik C, Johansson P, Andreasson B, Safai-Kutti S, Kutti J: **High PRV-1 mRNA expression, a diagnostic marker for polycythemia vera [abstract].** *Blood* 2002, **100**:3156a.
23. Klippel S, Strunck E, Temerinac S, Bench AJ, Meinhardt G, Mohr U, Leichte R, Green AR, Griesshammer M, Heimpel H, Pahl HL: **Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis.** *Blood* 2003, **102(10)**:3569-3574.
24. Bench AJ, Pahl HL: **Chromosomal abnormalities and molecular markers in myeloproliferative disorders.** *Semin Hematol* 2005, **42(4)**:196-205.
25. Cilloni D, Carturan S, Gottardi E, Messa F, Fava M, Defilippi I, Arruga F, Saglio G: **Usefulness of the quantitative assessment of PRV-1 gene expression for the diagnosis of polycythemia vera and essential thrombocythemia patients.** *Blood* 2004, **103(6)**:2428; author reply 2429.
26. Caruccio L, Bettinotti M, Director-Myska AE, Arthur DC, Stroncek D: **The gene overexpressed in polycythemia rubra vera, PRV-1, and the gene encoding a neutrophil alloantigen, NBI, are alleles of a single gene, CD177, in chromosome band 19q13.31.** *Transfusion* 2006, **46(3)**:441-447.
27. Stroncek DF, Caruccio L, Bettinotti M: **CD177: A member of the Ly-6 gene superfamily involved with neutrophil proliferation and polycythemia vera.** *J Transl Med* 2004, **2(1)**:8.
28. Gohring K, Wolff J, Doppel W, Schmidt KL, Fenchel K, Pralle H, Sibelius U, Bux J: **Neutrophil CD177 (NBI gp, HNA-2a) expression is increased in severe bacterial infections and polycythemia vera.** *Br J Haematol* 2004, **126(2)**:252-254.
29. Klippel S, Strunck E, Busse CE, Behringer D, Pahl HL: **Biochemical characterization of PRV-1, a novel hematopoietic cell surface receptor, which is overexpressed in polycythemia rubra vera.** *Blood* 2002, **100(7)**:2441-2448.
30. Ronne E, Pappot H, Grondahl-Hansen J, Hoyer-Hansen G, Plesner T, Hansen NE, Dano K: **The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria.** *Br J Haematol* 1995, **89(3)**:576-581.
31. Ihle JN: **Cytokine receptor signalling.** *Nature* 1995, **377(6550)**:591-594.
32. Berchtold S, Moriggl R, Gouilleux F, Silvennoinen O, Beisenherz C, Pfitzner E, Wissler M, Stocklin E, Groner B: **Cytokine receptor-independent, constitutively active variants of STAT5.** *J Biol Chem* 1997, **272(48)**:30237-30243.
33. Saharinen P, Vihinen M, Silvennoinen O: **Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.** *Mol Biol Cell* 2003, **14(4)**:1448-1459.
34. Lindauer K, Loerting T, Liedl KR, Kroemer RT: **Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation.** *Protein Eng* 2001, **14(1)**:27-37.
35. Luo H, Rose P, Barber D, Hanratty WP, Lee S, Roberts TM, D'Andrea AD, Dearolf CR: **Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways.** *Mol Cell Biol* 1997, **17(3)**:1562-1571.
36. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W: **A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera.** *Nature* 2005, **434(7037)**:1144-1148.
37. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR: **Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.** *Lancet* 2005, **365(9464)**:1054-1061.
38. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG: **Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.** *Cancer Cell* 2005, **7(4)**:387-397.
39. Kralovics R, Passamonti F, Buser AS, Teo S, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC: **A gain-of-function mutation of JAK2 in myeloproliferative disorders.** *New England Journal of Medicine* 2005, **352(17)**:1779-1790.
40. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, Zhao ZJ: **Identification of an acquired JAK2 mutation in polycythemia vera.** *J Biol Chem* 2005, **280(24)**:22788-22792.
41. Cazzola M, Passamonti F: **Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders.** *Haematologica - The Hematology Journal* 2006, **91(2)**:159-161.
42. Scott LM, Scott MA, Campbell PJ, Green AR: **Progenitors homozygous for the V617F JAK2 mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.** *Blood* 2006.
43. Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS, Sekeres MA, Maciejewski JP: **Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.** *Blood* 2006.
44. Kralovics R, Skoda RC: **Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders.** *Blood Rev* 2005, **19(1)**:1-13.
45. Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ, Gilliland DG, Tefferi A: **JAK2 mutation in essential thrombocythemia: clinical associations and long-term prognostic relevance.** *Br J Haematol* 2005, **131(2)**:208-213.
46. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden DT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan JW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR: **Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on JAK2 V617F mutation status: a prospective study.** *Lancet* 2005, **366(9501)**:1945-1953.



47. Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V, Longo G, Bosi A, Vannucchi AM: **Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.** *Leukemia* 2005, **19(10)**:1847-1849.
48. Kiladjian JJ, Elkassar N, Cassinat B, Hetet G, Giraudier S, Balitrand N, Conejero C, Briere J, Fenaux P, Chomienne C, Grandchamp B: **Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders.** *Leukemia* 2006, **20(6)**:1181-1183.
49. Sidon P, El Housni H, Dessars B, Heimann P: **The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors.** *Leukemia* 2006.
50. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P: **Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals.** *Blood* 1995, **86(8)**:3118-3122.
51. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV: **The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.** *Blood* 1998, **92(9)**:3362-3367.
52. Butt NM, Rojas JM, Wang L, Christmas SE, Abu-Eisha HM, Clark RE: **Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.** *Haematologica* 2005, **90(10)**:1315-1323.
53. Dong F, Brynes RK, Tidow N, Welte K, Lowenberg B, Touw IP: **Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia.** *N Engl J Med* 1995, **333(8)**:487-493.
54. Hunter MG, Jacob A, O'Donnell L C, Agler A, Druhan LJ, Coggeshall KM, Avalos BR: **Loss of SHIP and CIS recruitment to the granulocyte colony-stimulating factor receptor contribute to hyperproliferative responses in severe congenital neutropenia/acute myelogenous leukemia.** *J Immunol* 2004, **173(8)**:5036-5045.
55. Souyri M, Vigon I, Penciolelli JF, Heard JM, Tambourin P, Wendling F: **A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors.** *Cell* 1990, **63(6)**:1137-1147.
56. Wendling F, Varlet P, Charon M, Tambourin P: **MPLV: a retrovirus complex inducing an acute myeloproliferative leukemic disorder in adult mice.** *Virology* 1986, **149(2)**:242-246.
57. Sabath DF, Kaushansky K, Broudy VC: **Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding.** *Blood* 1999, **94(1)**:365-367.
58. Horikawa Y, Matsumura I, Hashimoto K, Shiraga M, Kosugi S, Tadokoro S, Kato T, Miyazaki H, Tomiyama Y, Kurata Y, Matsuzawa Y, Kanakura Y: **Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia.** *Blood* 1997, **90(10)**:4031-4038.
59. Moliterno AR, Hankins WD, Spivak JL: **Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.** *N Engl J Med* 1998, **338(9)**:572-580.
60. Moliterno AR, Spivak JL: **Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera.** *Blood* 1999, **94(8)**:2555-2561.
61. Westwood NB, Raj K, Messinezy M, Pearson TC: **Platelet expression of Mpl is diminished in reactive thrombocytosis and in myeloproliferative disorders but is normal in secondary erythrocytosis.** *Blood* 1999, **94(suppl. 1)**:491.
62. Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC: **An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia.** *Nat Genet* 1998, **18(1)**:49-52.
63. Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A, Tsuboi K, Nitta M, Miyazaki H, Iida S, Ueda R: **Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin.** *Blood* 2004, **103(11)**:4198-4200.
64. Moliterno AR, Williams DM, Gutierrez-Alamillo LI, Salvatori R, Ingersoll RG, Spivak JL: **Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis.** *Proc Natl Acad Sci U S A* 2004, **101(31)**:11444-11447.
65. Staerk J, Lacout C, Sato T, Smith SO, Vainchenker W, Constantinescu SN: **An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor.** *Blood* 2006, **107(5)**:1864-1871.
66. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, Deangelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL: **MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia.** *PLoS Med* 2006, **3(7)**:e270.
67. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Lit-zow MR, Gilliland DG, Tefferi A: **MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.** *Blood* 2006.
68. Thiele J, Kvasnicka HM: **Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders.** *Semin Thromb Hemost* 2006, **32(3)**:219-230.
69. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A: **The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.** *Blood* 2005, **106(4)**:1207-1209.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
http://www.biomedcentral.com/info/publishing\_adv.asp

